The ARPA-H Antigens Predicted for Broad Viral Efficacy through Computational Experimentation (APECx) program aims to use predictive modeling and machine learning tools to design proteins that can act as broadly effective antigens.
Funding for awardees varies in amount and is contingent upon the recipient meeting aggressive milestones specific to their project.
The APECx performers are:
- La Jolla Institute for Immunology focusing on beta and gamma-herpesvirus antigen and vaccine candidate development, including cytomegalovirus infections.
- Texas A&M Engineering Experiment Station focusing on data and tool integration across the program.
- University of Washington focusing on alpha and gamma-herpesvirus antigen and vaccine candidate development, including herpes simplex virus infections.
- Vaccine Company, Inc. focusing on vaccine development for flaviviruses, which include threats such as West Nile virus, dengue virus, and Zika virus.
- Vanderbilt University focusing on antigen design and vaccine candidate development against alphaviruses, such as Chikungunya virus and Eastern equine encephalitis virus.